Whitehawk Therapeutics Reports Narrower Q1 Loss, Extends Cash Runway into 2028
WHWK has more than doubled off its 52-week low of $1.53.
Summary
Whitehawk Therapeutics announced Q1 2026 financial results, reporting a narrower-than-expected net loss of $22.2 million and a cash balance of $123.0 million, extending its operational runway into 2028.
Key Events · Earnings and Guidance · WHWK
-
Q1 2026 Financial Results
Reported a net loss of $22.2 million for the quarter ended March 31, 2026, which was narrower than analyst estimates. This compares to a net income of $73.0 million in Q1 2025, which included a significant gain from the sale of a subsidiary.
-
Strong Cash Position and Runway
Cash, cash equivalents, and short-term investments totaled $123.0 million as of March 31, 2026. The company anticipates this capital will fund operations into 2028, providing a substantial runway for its clinical development.
-
Pipeline Progress
Continued enrollment in Phase 1 dose-escalation trials for HWK-007 and HWK-016. An Investigational New Drug (IND) application for HWK-206 is on track for submission in mid-2026, with Phase 1 recruitment planned for Q3 2026.
-
Increased R&D Investment
Research and development expenses rose to $17.2 million in Q1 2026, up from $8.8 million in Q1 2025, reflecting active investment in its next-generation antibody-drug conjugate (ADC) portfolio.
Analysis · WHWK · Life Sciences
Whitehawk Therapeutics reported a net loss of $22.2 million for Q1 2026, which was narrower than analyst expectations. This positive surprise, coupled with a strong cash position of $123.0 million as of March 31, 2026, provides an anticipated cash runway into 2028. For a clinical-stage oncology company, this extended runway is a critical de-risking factor, allowing continued progress on its pipeline, including ongoing Phase 1 trials for HWK-007 and HWK-016, and an Investigational New Drug (IND) submission for HWK-206 planned for mid-2026. The increased R&D expenses reflect active pipeline development.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WHWK was trading at $4.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $205.1M. The 52-week trading range was $1.53 to $4.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.